AstraZeneca has made available vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. A Risk Evaluation and Mitigation Strategy (REMS) is required for vandetanib due to the risks of QT prolongation, torsades de pointes, and sudden death. Only prescribers who are certified through the Vandetanib REMS Program will be able to prescribe vandetanib.
Vandetanib will be available solely though the pharmacy business unit of Biologics, Inc. No trade name has been established at this time.
To learn about the specific REMS requirements and to enroll in the Vandetanib REMS Program, please call (800) 236-9933 or visit www.vandetanibrems.com.